Diabetes drug 'Actos' to be pulled from market because of risk of bladder cancer

Published: 2011-06-15 06:56:00

Updated: 2011-06-15 06:56:00

Japanese pharmaceutical company Takeda’s blockbuster anti-diabetes pill “Actos (pioglitazone)” faces being banned in the Korean market as the Korea Food and Drug Administration (KFDA) on Monday ordered doctors to refrain from prescribing it for type-2 diabetes patients due to bladder cancer risk.

Only when there are no alternative pills to be prescribed, according to the KFDA. However, give...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.